Analysis of Ginkgo Bioworks' Q3 results and business model, with a focus on growth, customer acquisition and cash flow ...

BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...

Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors. Ginkgo Bioworks Holdings, Inc.

Boston-based Ginkgo Bioworks has canceled plans to move into a 250K SF lab data center and will exit two Cambridge locations ...

One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Q3 2024 Earnings Call Transcript November 12, 2024 Megan LeDuc: Good evening. I’m Megan LeDuc, Manager of Investor Relations ...

Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?